JP7577314B2 - 改変型ｄｎａｓｅ酵素及び治療における使用 - Google Patents
改変型ｄｎａｓｅ酵素及び治療における使用 Download PDFInfo
- Publication number
- JP7577314B2 JP7577314B2 JP2020531567A JP2020531567A JP7577314B2 JP 7577314 B2 JP7577314 B2 JP 7577314B2 JP 2020531567 A JP2020531567 A JP 2020531567A JP 2020531567 A JP2020531567 A JP 2020531567A JP 7577314 B2 JP7577314 B2 JP 7577314B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- dnase
- enzyme
- dnase1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004190 Enzymes Human genes 0.000 title claims description 169
- 108090000790 Enzymes Proteins 0.000 title claims description 169
- 230000001225 therapeutic effect Effects 0.000 title description 16
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 217
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 217
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 148
- 230000000694 effects Effects 0.000 claims description 148
- 108010077544 Chromatin Proteins 0.000 claims description 126
- 210000003483 chromatin Anatomy 0.000 claims description 126
- 230000015556 catabolic process Effects 0.000 claims description 124
- 238000006731 degradation reaction Methods 0.000 claims description 124
- 108090000623 proteins and genes Proteins 0.000 claims description 101
- 102000004169 proteins and genes Human genes 0.000 claims description 97
- 210000000440 neutrophil Anatomy 0.000 claims description 69
- 230000035772 mutation Effects 0.000 claims description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims description 52
- 210000004899 c-terminal region Anatomy 0.000 claims description 50
- 230000001965 increasing effect Effects 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 45
- 230000001684 chronic effect Effects 0.000 claims description 34
- 208000027418 Wounds and injury Diseases 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 30
- 206010029379 Neutrophilia Diseases 0.000 claims description 29
- 238000002560 therapeutic procedure Methods 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 208000027866 inflammatory disease Diseases 0.000 claims description 28
- 238000012217 deletion Methods 0.000 claims description 27
- 230000037430 deletion Effects 0.000 claims description 27
- 206010053648 Vascular occlusion Diseases 0.000 claims description 26
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 26
- 101150063735 DNASE1 gene Proteins 0.000 claims description 22
- 206010040047 Sepsis Diseases 0.000 claims description 22
- 230000001154 acute effect Effects 0.000 claims description 22
- 230000006378 damage Effects 0.000 claims description 21
- 101150041872 DNASE1L3 gene Proteins 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 20
- 210000000056 organ Anatomy 0.000 claims description 20
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 19
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 16
- 208000014674 injury Diseases 0.000 claims description 16
- 206010052428 Wound Diseases 0.000 claims description 15
- 208000020832 chronic kidney disease Diseases 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 14
- 206010063837 Reperfusion injury Diseases 0.000 claims description 14
- 208000007536 Thrombosis Diseases 0.000 claims description 14
- 201000005569 Gout Diseases 0.000 claims description 13
- 206010033645 Pancreatitis Diseases 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 206010069351 acute lung injury Diseases 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 12
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 11
- 206010003598 Atelectasis Diseases 0.000 claims description 11
- 201000001320 Atherosclerosis Diseases 0.000 claims description 11
- 206010014568 Empyema Diseases 0.000 claims description 11
- 208000004852 Lung Injury Diseases 0.000 claims description 11
- 208000007123 Pulmonary Atelectasis Diseases 0.000 claims description 11
- 208000033626 Renal failure acute Diseases 0.000 claims description 11
- 208000006011 Stroke Diseases 0.000 claims description 11
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 11
- 201000011040 acute kidney failure Diseases 0.000 claims description 11
- 208000006673 asthma Diseases 0.000 claims description 11
- 206010006451 bronchitis Diseases 0.000 claims description 11
- 231100000515 lung injury Toxicity 0.000 claims description 11
- 208000010125 myocardial infarction Diseases 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 claims description 10
- 201000002818 limb ischemia Diseases 0.000 claims description 10
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 9
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims description 9
- 208000025865 Ulcer Diseases 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 208000007056 sickle cell anemia Diseases 0.000 claims description 9
- 231100000397 ulcer Toxicity 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 8
- 206010061481 Renal injury Diseases 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 206010025135 lupus erythematosus Diseases 0.000 claims description 8
- 208000030090 Acute Disease Diseases 0.000 claims description 7
- 201000010789 Spermatic Cord Torsion Diseases 0.000 claims description 7
- 206010043356 Testicular torsion Diseases 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010006448 Bronchiolitis Diseases 0.000 claims description 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 6
- 208000025678 Ciliary Motility disease Diseases 0.000 claims description 6
- 206010018852 Haematoma Diseases 0.000 claims description 6
- 206010019027 Haemothorax Diseases 0.000 claims description 6
- 206010067125 Liver injury Diseases 0.000 claims description 6
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 6
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims description 6
- 208000011623 Obstructive Lung disease Diseases 0.000 claims description 6
- 206010048685 Oral infection Diseases 0.000 claims description 6
- 208000005141 Otitis Diseases 0.000 claims description 6
- 208000002151 Pleural effusion Diseases 0.000 claims description 6
- 206010061351 Pleural infection Diseases 0.000 claims description 6
- 206010040914 Skin reaction Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 6
- 229940037003 alum Drugs 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 6
- 230000023555 blood coagulation Effects 0.000 claims description 6
- 201000009267 bronchiectasis Diseases 0.000 claims description 6
- 208000007451 chronic bronchitis Diseases 0.000 claims description 6
- 208000019258 ear infection Diseases 0.000 claims description 6
- 206010014665 endocarditis Diseases 0.000 claims description 6
- 231100000753 hepatic injury Toxicity 0.000 claims description 6
- 208000000509 infertility Diseases 0.000 claims description 6
- 230000036512 infertility Effects 0.000 claims description 6
- 231100000535 infertility Toxicity 0.000 claims description 6
- 230000002262 irrigation Effects 0.000 claims description 6
- 238000003973 irrigation Methods 0.000 claims description 6
- 208000037806 kidney injury Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 208000004593 pneumococcal meningitis Diseases 0.000 claims description 6
- 230000002980 postoperative effect Effects 0.000 claims description 6
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims description 6
- 238000002435 rhinoplasty Methods 0.000 claims description 6
- 230000035483 skin reaction Effects 0.000 claims description 6
- 231100000430 skin reaction Toxicity 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000034706 Graft dysfunction Diseases 0.000 claims description 5
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 208000004530 Primary Graft Dysfunction Diseases 0.000 claims description 5
- 230000002776 aggregation Effects 0.000 claims description 5
- 238000004220 aggregation Methods 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 230000000391 smoking effect Effects 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010014522 Embolism venous Diseases 0.000 claims description 4
- 206010024404 Leukostasis Diseases 0.000 claims description 4
- 208000037581 Persistent Infection Diseases 0.000 claims description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 230000010398 acute inflammatory response Effects 0.000 claims description 4
- 230000012085 chronic inflammatory response Effects 0.000 claims description 4
- 201000007647 intestinal volvulus Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 230000002537 thrombolytic effect Effects 0.000 claims description 4
- 208000037816 tissue injury Diseases 0.000 claims description 4
- 230000000472 traumatic effect Effects 0.000 claims description 4
- 208000004043 venous thromboembolism Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims 1
- 206010048628 rheumatoid vasculitis Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 193
- 108020004414 DNA Proteins 0.000 description 180
- 229940088598 enzyme Drugs 0.000 description 164
- 241000699670 Mus sp. Species 0.000 description 145
- 229940024606 amino acid Drugs 0.000 description 145
- 150000001413 amino acids Chemical class 0.000 description 143
- 238000006467 substitution reaction Methods 0.000 description 127
- 238000000034 method Methods 0.000 description 110
- 241000282414 Homo sapiens Species 0.000 description 97
- 235000018102 proteins Nutrition 0.000 description 89
- 230000014509 gene expression Effects 0.000 description 60
- 210000002966 serum Anatomy 0.000 description 50
- 102220356735 c.92A>G Human genes 0.000 description 49
- 210000002381 plasma Anatomy 0.000 description 47
- 102000053602 DNA Human genes 0.000 description 46
- 238000000338 in vitro Methods 0.000 description 43
- 230000004048 modification Effects 0.000 description 43
- 238000012986 modification Methods 0.000 description 43
- 241000699666 Mus <mouse, genus> Species 0.000 description 40
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- 239000013612 plasmid Substances 0.000 description 37
- 230000013595 glycosylation Effects 0.000 description 31
- 238000006206 glycosylation reaction Methods 0.000 description 31
- 239000004475 Arginine Substances 0.000 description 29
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 29
- 230000000593 degrading effect Effects 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 102000007469 Actins Human genes 0.000 description 26
- 108010085238 Actins Proteins 0.000 description 26
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 26
- 238000000246 agarose gel electrophoresis Methods 0.000 description 24
- 108010076504 Protein Sorting Signals Proteins 0.000 description 23
- 238000012546 transfer Methods 0.000 description 23
- 241000235058 Komagataella pastoris Species 0.000 description 22
- 238000009825 accumulation Methods 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 22
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 21
- 102200155746 rs121918466 Human genes 0.000 description 21
- 102000035195 Peptidases Human genes 0.000 description 20
- 108091005804 Peptidases Proteins 0.000 description 20
- 239000004365 Protease Substances 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 238000007792 addition Methods 0.000 description 19
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 18
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 17
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 17
- 238000003780 insertion Methods 0.000 description 17
- 230000037431 insertion Effects 0.000 description 17
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 16
- 102200024576 rs104894383 Human genes 0.000 description 16
- 102220617067 Arginine-glutamic acid dipeptide repeats protein_Q177K_mutation Human genes 0.000 description 15
- 108010073385 Fibrin Proteins 0.000 description 15
- 102000009123 Fibrin Human genes 0.000 description 15
- 239000004472 Lysine Substances 0.000 description 15
- 210000004204 blood vessel Anatomy 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 229950003499 fibrin Drugs 0.000 description 15
- 238000007805 zymography Methods 0.000 description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 102000003896 Myeloperoxidases Human genes 0.000 description 14
- 108090000235 Myeloperoxidases Proteins 0.000 description 14
- 230000002685 pulmonary effect Effects 0.000 description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 13
- 230000001640 apoptogenic effect Effects 0.000 description 13
- 230000002255 enzymatic effect Effects 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 102220621769 Pentraxin-4_H86N_mutation Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000009429 distress Effects 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 210000001550 testis Anatomy 0.000 description 12
- 210000003932 urinary bladder Anatomy 0.000 description 12
- 210000001177 vas deferen Anatomy 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 108010047303 von Willebrand Factor Proteins 0.000 description 12
- 102100036537 von Willebrand factor Human genes 0.000 description 12
- 229960001134 von willebrand factor Drugs 0.000 description 12
- -1 3-15 amino acids Chemical class 0.000 description 11
- 102100029462 Sodium-dependent lysophosphatidylcholine symporter 1 Human genes 0.000 description 11
- 101710185583 Sodium-dependent lysophosphatidylcholine symporter 1 Proteins 0.000 description 11
- 230000004087 circulation Effects 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 238000001361 intraarterial administration Methods 0.000 description 11
- 238000001990 intravenous administration Methods 0.000 description 11
- 238000011068 loading method Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 108091035707 Consensus sequence Proteins 0.000 description 10
- 101000845618 Homo sapiens Deoxyribonuclease gamma Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 10
- 238000012744 immunostaining Methods 0.000 description 10
- 230000002779 inactivation Effects 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000011002 quantification Methods 0.000 description 10
- 238000002864 sequence alignment Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 230000000451 tissue damage Effects 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 108010033040 Histones Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 102000054371 human DNASE1L3 Human genes 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 238000001543 one-way ANOVA Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 231100000827 tissue damage Toxicity 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 102220499754 ADP/ATP translocase 3_D109K_mutation Human genes 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 206010021113 Hypothermia Diseases 0.000 description 8
- 102220468814 Peptidyl-tRNA hydrolase ICT1, mitochondrial_N76K_mutation Human genes 0.000 description 8
- 208000031737 Tissue Adhesions Diseases 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 108010067396 dornase alfa Proteins 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 208000006750 hematuria Diseases 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 230000002631 hypothermal effect Effects 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 208000017169 kidney disease Diseases 0.000 description 8
- 238000001325 log-rank test Methods 0.000 description 8
- 230000008816 organ damage Effects 0.000 description 8
- 238000010149 post-hoc-test Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 102220224489 rs779269031 Human genes 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 206010010741 Conjunctivitis Diseases 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 102000006947 Histones Human genes 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 7
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 7
- 102000002151 Microfilament Proteins Human genes 0.000 description 7
- 108010040897 Microfilament Proteins Proteins 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 210000000013 bile duct Anatomy 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 208000003167 cholangitis Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 7
- 230000000302 ischemic effect Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 208000004396 mastitis Diseases 0.000 description 7
- 102220133487 rs149819112 Human genes 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 6
- 206010061876 Obstruction Diseases 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000000941 bile Anatomy 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 125000002091 cationic group Chemical group 0.000 description 6
- 210000003459 common hepatic duct Anatomy 0.000 description 6
- 210000001096 cystic duct Anatomy 0.000 description 6
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 6
- 210000003204 ejaculatory duct Anatomy 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 210000000232 gallbladder Anatomy 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 6
- 102200040999 rs121917770 Human genes 0.000 description 6
- 102220127644 rs201962705 Human genes 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000004797 therapeutic response Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 210000000626 ureter Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 5
- 208000005230 Leg Ulcer Diseases 0.000 description 5
- 108091061960 Naked DNA Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 208000037549 Shiga toxin-associated hemolytic uremic syndrome Diseases 0.000 description 5
- 102220509841 Transcription initiation factor TFIID subunit 11_T68R_mutation Human genes 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000013611 chromosomal DNA Substances 0.000 description 5
- 229960003850 dabigatran Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 238000013467 fragmentation Methods 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 230000009716 hepatic expression Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 208000010157 sclerosing cholangitis Diseases 0.000 description 5
- 201000009890 sinusitis Diseases 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 101100091046 Caenorhabditis elegans rmd-1 gene Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000007399 DNA isolation Methods 0.000 description 4
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 210000003037 cerebral aqueduct Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 208000007475 hemolytic anemia Diseases 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102200151154 rs386834188 Human genes 0.000 description 4
- 229960004533 streptodornase Drugs 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102220561378 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT5_N86H_mutation Human genes 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 101800004229 Cathelin-related antimicrobial peptide Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 108700026226 TATA Box Proteins 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 210000001723 extracellular space Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000009117 preventive therapy Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 102220068370 rs767670214 Human genes 0.000 description 3
- 102200037604 rs879254418 Human genes 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- DDPKBJZLAXLQGZ-KBIXCLLPSA-N Ala-Val-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O DDPKBJZLAXLQGZ-KBIXCLLPSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 102220537924 Biogenesis of lysosome-related organelles complex 1 subunit 5_N128D_mutation Human genes 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102100031149 Deoxyribonuclease gamma Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 102100033174 Neutrophil elastase Human genes 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 206010060932 Postoperative adhesion Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 101150071324 TRAP1 gene Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000009144 enzymatic modification Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000055827 human SLC6A2 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 102200120159 rs1799971 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008718 systemic inflammatory response Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- 102220643831 39S ribosomal protein L9, mitochondrial_N40A_mutation Human genes 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100039445 Cortexin-3 Human genes 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 101710206036 Deoxyribonuclease-1 Proteins 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 101100061721 Homo sapiens CTXN3 gene Proteins 0.000 description 1
- 101000863721 Homo sapiens Deoxyribonuclease-1 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000746384 Mus musculus Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 240000007019 Oxalis corniculata Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150094373 Padi4 gene Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 206010043298 Testicular atrophy Diseases 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000010788 atrophy of testis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011965 cell line development Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229960000288 dabigatran etexilate Drugs 0.000 description 1
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 108010031616 deoxyribonuclease gamma Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940066336 pradaxa Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102220013900 rs397516803 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000009003 standardized kity Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 231100001044 testicular atrophy Toxicity 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547220P | 2017-08-18 | 2017-08-18 | |
| US62/547,220 | 2017-08-18 | ||
| US201762611166P | 2017-12-28 | 2017-12-28 | |
| US62/611,166 | 2017-12-28 | ||
| PCT/US2018/047084 WO2019036719A2 (en) | 2017-08-18 | 2018-08-20 | GENETICALLY MODIFIED DNASE ENZYMES AND THEIR USE IN THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534865A JP2020534865A (ja) | 2020-12-03 |
| JP2020534865A5 JP2020534865A5 (https=) | 2021-09-30 |
| JP7577314B2 true JP7577314B2 (ja) | 2024-11-05 |
Family
ID=65362608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531567A Active JP7577314B2 (ja) | 2017-08-18 | 2018-08-20 | 改変型ｄｎａｓｅ酵素及び治療における使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US10696956B2 (https=) |
| EP (2) | EP3668972B8 (https=) |
| JP (1) | JP7577314B2 (https=) |
| KR (2) | KR20250073498A (https=) |
| CN (1) | CN111566207A (https=) |
| AU (1) | AU2018318313B2 (https=) |
| BR (1) | BR112020003403A2 (https=) |
| CA (1) | CA3073317A1 (https=) |
| DK (1) | DK3668972T3 (https=) |
| ES (1) | ES3008982T3 (https=) |
| IL (2) | IL272715B2 (https=) |
| MX (1) | MX2020001913A (https=) |
| SG (1) | SG11202001445XA (https=) |
| UA (1) | UA129696C2 (https=) |
| WO (1) | WO2019036719A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246905B2 (en) | 2016-08-15 | 2022-02-15 | President And Fellows Of Harvard College | Treating infections using IdsD from Proteus mirabilis |
| EP3351263A1 (en) * | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| DK3668972T3 (da) | 2017-08-18 | 2025-01-13 | Neutrolis Inc | Konstruerede dnase-enzymer og anvendelse i terapi |
| AU2019209770B2 (en) | 2018-01-16 | 2025-07-31 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
| IL325846A (en) * | 2018-10-08 | 2026-03-01 | Neutrolis Inc | Engineering deoxyribonuclease enzymes for manufacturing and medicine |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| WO2020163264A1 (en) * | 2019-02-04 | 2020-08-13 | Neutrolis, Inc. | Engineered human extracellular dnase enzymes for drug candidate selection |
| US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
| WO2020227415A1 (en) * | 2019-05-06 | 2020-11-12 | President And Fellows Of Harvard College | Dna-degrading proteins and uses thereof |
| WO2021071733A1 (en) * | 2019-10-07 | 2021-04-15 | Texas Tech University System | Mutant dnase1l3 with improved serum half-life |
| IL294114A (en) * | 2020-01-11 | 2022-08-01 | Univ Yale | Preparations and methods for the treatment, improvement and/or prevention of diseases or disorders caused by or related to dnase1 and/or dnase1l3 |
| WO2021168413A1 (en) * | 2020-02-20 | 2021-08-26 | Neutrolis, Inc. | Basic domain-deleted dnase1-like 3 and uses thereof |
| US20230174944A1 (en) * | 2020-04-15 | 2023-06-08 | Cartesian Therapeutics, Inc. | Engineered cells secreting therapeutic enzymes |
| US20230226138A1 (en) * | 2020-06-01 | 2023-07-20 | Black Cat Bio Limited | Compositions and methods for treating infections and netopathy |
| EP4161645A4 (en) * | 2020-06-08 | 2023-11-01 | Yale University | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING COAGULOPATHY AND/OR SEPSIS IN PATIENTS WITH BACTERIAL AND/OR VIRAL INFECTIONS |
| EP4225903A1 (en) | 2020-10-07 | 2023-08-16 | Protalix Ltd. | Long-acting dnase |
| WO2025076525A1 (en) * | 2023-10-06 | 2025-04-10 | Neutrolis, Inc. | Biomarker and precision therapy for inflammatory disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US6656685B2 (en) | 2001-01-29 | 2003-12-02 | Ventana Medical Systems, Inc. | Hybridization buffers using low molecular weight dextran sulfate and methods for their use |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US20040138156A1 (en) | 2002-02-26 | 2004-07-15 | Schneider Michael C | Therapeutic regulation of deoxyribonuclease-1-like-3 activity |
| US9248166B2 (en) | 2003-07-14 | 2016-02-02 | Cls Therapeutics Limited | Method for treating oncological diseases |
| WO2006130034A1 (fr) | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| RU2269356C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| EP2416156B1 (en) | 2006-10-18 | 2015-12-30 | Periness Ltd. | Method for determining a male fertility status |
| US20090305345A1 (en) | 2006-10-23 | 2009-12-10 | Medical Research Council | Polymerase |
| AU2008279550B2 (en) * | 2007-06-21 | 2012-08-09 | Angelica Therapeutics, Inc. | Modified toxins |
| MX341084B (es) * | 2009-11-02 | 2016-08-05 | Univ Washington | Composiciones de nucleasas terapéuticas y métodos. |
| EP2561367A1 (en) | 2010-04-22 | 2013-02-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| CN107188970A (zh) | 2010-06-04 | 2017-09-22 | 株式会社蒂奥姆生物 | 具有因子vii活性的融合蛋白质 |
| WO2012106264A2 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of Columbia University In The City Of New York | Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections |
| WO2012166611A2 (en) | 2011-05-27 | 2012-12-06 | Immune Disease Institute, Inc. | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| US9867871B2 (en) | 2011-12-12 | 2018-01-16 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| GB201208879D0 (en) | 2012-05-21 | 2012-07-04 | London School Hygiene & Tropical Medicine | Therapeutic for treating Clostridium difficile infection |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| CA2935748A1 (en) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| CN107249621A (zh) | 2014-09-08 | 2017-10-13 | 哥谭生物制药股份有限公司 | 用于治疗肺结节病的粘液溶解剂 |
| WO2016118476A1 (en) | 2015-01-20 | 2016-07-28 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
| EP3265814B1 (en) | 2015-03-01 | 2020-11-18 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
| EP3273238A1 (en) | 2016-07-22 | 2018-01-24 | Universitätsklinikum Hamburg-Eppendorf | Immunodiagnostic detection of anti-neutrophil antibodies |
| CA3036926C (en) | 2016-09-30 | 2022-05-31 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| EP3570667B1 (en) | 2017-01-20 | 2022-11-16 | Neutrolis Inc. | Animal model for drug development |
| DK3668972T3 (da) | 2017-08-18 | 2025-01-13 | Neutrolis Inc | Konstruerede dnase-enzymer og anvendelse i terapi |
-
2018
- 2018-08-20 DK DK18846060.4T patent/DK3668972T3/da active
- 2018-08-20 KR KR1020257014953A patent/KR20250073498A/ko active Pending
- 2018-08-20 SG SG11202001445XA patent/SG11202001445XA/en unknown
- 2018-08-20 CN CN201880068103.8A patent/CN111566207A/zh active Pending
- 2018-08-20 IL IL272715A patent/IL272715B2/en unknown
- 2018-08-20 KR KR1020207007703A patent/KR102806169B1/ko active Active
- 2018-08-20 EP EP18846060.4A patent/EP3668972B8/en active Active
- 2018-08-20 BR BR112020003403-7A patent/BR112020003403A2/pt unknown
- 2018-08-20 EP EP24205258.7A patent/EP4509135A3/en active Pending
- 2018-08-20 AU AU2018318313A patent/AU2018318313B2/en active Active
- 2018-08-20 WO PCT/US2018/047084 patent/WO2019036719A2/en not_active Ceased
- 2018-08-20 CA CA3073317A patent/CA3073317A1/en active Pending
- 2018-08-20 UA UAA202001869A patent/UA129696C2/uk unknown
- 2018-08-20 IL IL317968A patent/IL317968A/en unknown
- 2018-08-20 MX MX2020001913A patent/MX2020001913A/es unknown
- 2018-08-20 ES ES18846060T patent/ES3008982T3/es active Active
- 2018-08-20 JP JP2020531567A patent/JP7577314B2/ja active Active
-
2019
- 2019-08-02 US US16/530,141 patent/US10696956B2/en active Active
-
2020
- 2020-07-15 US US16/929,980 patent/US10801019B1/en active Active
- 2020-09-11 US US17/018,642 patent/US11046942B2/en active Active
- 2020-10-12 US US17/068,105 patent/US11046943B2/en active Active
-
2021
- 2021-03-05 US US17/193,455 patent/US20210277372A1/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| Biochem. J.，2005年，Vol. 389，pp. 355-364，figure 1 |
| FEBS，2009年，Vol. 276，pp. 1059-1073 |
| Journal of Thrombosis and Haemostasis，2015年，Vol. 13，pp. 732-742 |
| Molecular Therapy，2002年，Vol. 6, No. 1，pp. 35-42 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7577314B2 (ja) | 改変型ｄｎａｓｅ酵素及び治療における使用 | |
| Englert et al. | Targeting NETs using dual-active DNase1 variants | |
| EP2364165B1 (en) | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | |
| US20210085762A1 (en) | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same | |
| CA2697583C (en) | Antidotes for factor xa inhibitors and methods of using the same | |
| JP5761782B2 (ja) | 改変第ｖｉｉ因子ポリペプチド及びその使用 | |
| EP2414517B1 (en) | Antidotes for factor xa inhibitors and methods of using the same | |
| Cioni et al. | Use of exogenous enzymes in human therapy: approved drugs and potential applications | |
| JP2024123142A (ja) | 抗血栓症作用および抗炎症作用を有する、第ｘｉ因子に対する新規ヒト化抗体およびその使用 | |
| AU2004290869A1 (en) | Therapeutic use of factor XI | |
| EA049198B1 (ru) | СКОНСТРУИРОВАННЫЕ ФЕРМЕНТЫ ДНКазы И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| HK40034165A (en) | Engineered dnase enzymes and use in therapy | |
| KR20230147138A (ko) | Adamts13 변이체 | |
| Kolev et al. | Targeting NETs using dual-active DNase1 variants | |
| HK1161138B (en) | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | |
| HK1161138A (en) | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | |
| WO2012031240A2 (en) | Therapeutics for trauma induced factor v consumptive coagulopathy | |
| HK1167346B (en) | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding | |
| HK1162584B (en) | Antidotes for factor xa inhibitors and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200407 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200220 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200409 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20200407 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210818 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220920 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230807 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231108 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240613 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240619 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240917 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241016 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7577314 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |